How much revenue does Jiangsu Yahong Meditech make?

Jiangsu Yahong Meditech reported 277.12 million CNY in revenue for fiscal year 2025, up 37.5% from 201.56 million CNY in fiscal year 2024. In Q1 2026 revenue was 71.09 million CNY.

What companies are similar to Jiangsu Yahong Meditech?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS), InventisBio Co., Limited (688382.SS), Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS), Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS).

Jiangsu Yahong Meditech Co., Ltd. (688176.SS) Stock

About Jiangsu Yahong Meditech Co., Ltd.

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-...

At a glance

Jiangsu Yahong Meditech reported revenue of 277.12 million CNY for fiscal year 2025, up 37.5% from fiscal year 2024, and net income of -416.38 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 71.09 million CNY, up 16.3% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.